Heliyon,
Год журнала:
2024,
Номер
10(5), С. e27325 - e27325
Опубликована: Фев. 29, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
the
most
common
cause
of
chronic
throughout
world.
Hepatocellular
carcinoma
(HCC)
and
cirrhosis
can
result
from
nonalcoholic
steatohepatitis
(NASH),
severe
stage
NAFLD
progression.
By
some
estimates,
affects
almost
one-third
world's
population,
which
completely
new
serious
public
health
issue.
Unfortunately,
diagnosed
by
exclusion,
gold
standard
for
identifying
NAFLD/NASH
reliably
measuring
fibrosis
remains
biopsy,
an
invasive,
costly,
time-consuming
procedure
involves
variable
inter-observer
diagnosis.
With
progress
omics
imaging
techniques,
numerous
non-invasive
serological
assays
have
been
generated
developed.
On
basis
these
developments,
biomarkers
techniques
combined
to
increase
diagnostic
accuracy.
This
review
provides
information
diagnosis
assessment
in
clinical
practice
going
forward
may
assist
clinician
making
early
accurate
proposing
a
cost-effective
patient
surveillance.
We
discuss
newly
identified
validated
methods
biopsy-confirmed
studies
their
implementation
practice,
encompassing
differentiation,
assessment,
progression
monitoring.
A
series
tests,
including
20-carboxy
arachidonic
acid
(20-COOH
AA)
13,14-dihydro-15-keto
prostaglandin
D2
(dhk
PGD2),
were
found
be
potentially
tests
diagnosing
NAFLD.
Additionally,
Three-dimensional
magnetic
resonance
(3D-MRE),
combination
FM-fibro
index
Liver
stiffness
measurement
(FM-fibro
LSM
index)
machine
learning
algorithm
(MLA)
are
more
than
other
assessing
fibrosis.
However,
it
essential
use
bigger
cohort
corroborate
number
with
extremely
elevated
values.
New England Journal of Medicine,
Год журнала:
2024,
Номер
391(4), С. 311 - 319
Опубликована: Июнь 7, 2024
BackgroundDual
agonism
of
glucagon
receptor
and
glucagon-like
peptide-1
(GLP-1)
may
be
more
effective
than
GLP-1
alone
for
treating
metabolic
dysfunction–associated
steatohepatitis
(MASH).
The
efficacy
safety
survodutide
(a
dual
agonist
receptor)
in
persons
with
MASH
liver
fibrosis
are
unclear.MethodsIn
this
48-week,
phase
2
trial,
we
randomly
assigned
adults
biopsy-confirmed
stage
F1
through
F3
a
1:1:1:1
ratio
to
receive
once-weekly
subcutaneous
injections
at
dose
2.4,
4.8,
or
6.0
mg
placebo.
trial
had
two
phases:
24-week
rapid-dose-escalation
phase,
followed
by
maintenance
phase.
primary
end
point
was
histologic
improvement
(reduction)
no
worsening
fibrosis.
Secondary
points
included
decrease
fat
content
least
30%
biopsy-assessed
one
stage.ResultsA
total
293
participants
received
Improvement
occurred
47%
the
2.4-mg
group,
62%
those
4.8-mg
43%
6.0-mg
as
compared
14%
placebo
group
(P<0.001
quadratic
dose–response
curve
best-fitting
model).
A
63%
67%
57%
group;
34%,
36%,
22%,
respectively.
Adverse
events
that
were
frequent
nausea
(66%
vs.
23%),
diarrhea
(49%
vomiting
(41%
4%);
serious
adverse
8%
7%
placebo.ConclusionsSurvodutide
superior
respect
without
fibrosis,
warranting
further
investigation
3
trials.
(Funded
Boehringer
Ingelheim;
1404-0043
ClinicalTrials.gov
number,
NCT04771273;
EudraCT
2020-002723-11.)
Clinical and Molecular Hepatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 19, 2024
As
the
rates
of
obesity
and
type
2
diabetes
(T2D)
continue
to
increase
globally,
so
does
prevalence
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD).
Currently,
38%
all
adults
7-14%
children
adolescents
have
MASLD.
By
2040,
MASLD
rate
for
is
projected
over
55%.
Although
many
with
will
not
develop
progressive
disease,
given
vast
number
patients
MASLD,
it
has
now
become
top
indication
transplant
in
United
States
those
hepatocellular
carcinoma
(HCC)
women.
However,
most
common
cause
mortality
among
remains
death
cardiovascular
diseases.
In
addition
outcomes
(cirrhosis
HCC),
increased
risk
developing
de-novo
T2D,
chronic
kidney
sarcopenia
extrahepatic
cancers.
Furthermore,
decreased
health
related
quality
life,
work
productivity,
fatigue
healthcare
resource
utilization
substantial
economic
burden.
Similar
other
lifestyle
interventions
heathy
diet
physical
activity
remain
cornerstone
managing
these
patients.
a
T2D
drugs
are
available
treat
co-morbid
Resmetirom
only
MASH-targeted
medication
that
was
recently
approved
by
Federal
Drug
Administration
use
stage
2-3
fibrosis.
The
following
review
provides
an
overview
epidemiology,
its
factors
demonstrates
without
further
global
initiatives,
may
increase.
Obesity Facts,
Год журнала:
2024,
Номер
17(4), С. 374 - 444
Опубликована: Янв. 1, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
termed
non-alcoholic
fatty
(NAFLD),
is
defined
as
(SLD)
in
the
presence
of
one
or
more
cardiometabolic
risk
factor(s)
and
absence
harmful
alcohol
intake.
The
spectrum
MASLD
includes
steatosis,
metabolic
steatohepatitis
(MASH,
NASH),
fibrosis,
cirrhosis
MASH-related
hepatocellular
carcinoma
(HCC).
This
joint
EASL-EASD-EASO
guideline
provides
an
update
on
definitions,
prevention,
screening,
diagnosis
treatment
for
MASLD.
Case-finding
strategies
with
using
non-invasive
tests,
should
be
applied
individuals
factors,
abnormal
enzymes,
and/or
radiological
signs
hepatic
particularly
type
2
diabetes
(T2D)
obesity
additional
factor(s).
A
stepwise
approach
blood-based
scores
(such
FIB-4)
and,
sequentially,
imaging
techniques
transient
elastography)
suitable
to
rule-out/in
advanced
which
predictive
liver-related
outcomes.
In
adults
MASLD,
lifestyle
modification
-
including
weight
loss,
dietary
changes,
physical
exercise
discouraging
consumption
well
optimal
management
comorbidities
use
incretin-based
therapies
(e.g.
semaglutide,
tirzepatide)
T2D
obesity,
if
indicated
advised.
Bariatric
surgery
also
option
obesity.
If
locally
approved
dependent
label,
non-cirrhotic
MASH
significant
fibrosis
(stage
≥2)
considered
a
MASH-targeted
resmetirom,
demonstrated
histological
effectiveness
acceptable
safety
tolerability
profile.
No
pharmacotherapy
can
currently
recommended
cirrhotic
stage.
Management
adaptations
drugs,
nutritional
counselling,
surveillance
portal
hypertension
HCC,
transplantation
decompensated
cirrhosis.
Frontiers in Cell and Developmental Biology,
Год журнала:
2024,
Номер
12
Опубликована: Июль 16, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
known
as
non-alcoholic
fatty
(NAFLD),
is
the
most
common
disorder
worldwide,
with
an
estimated
global
prevalence
of
more
than
31%.
steatohepatitis
(MASH),
formerly
(NASH),
a
progressive
form
MASLD
characterized
by
hepatic
steatosis,
inflammation,
and
fibrosis.
This
review
aims
to
provide
comprehensive
analysis
extrahepatic
manifestations
MASH,
focusing
on
chronic
diseases
related
cardiovascular,
muscular,
renal
systems.
A
systematic
published
studies
literature
was
conducted
summarize
findings
systemic
impacts
MASH.
The
focused
association
MASH
metabolic
comorbidities,
cardiovascular
mortality,
sarcopenia,
kidney
disease.
Mechanistic
insights
into
concept
lipotoxic
inflammatory
"spill
over"
from
MASH-affected
were
also
explored.
are
highly
associated
(50%-80%)
other
comorbidities
such
impaired
insulin
response,
type
2
diabetes,
dyslipidemia,
hypertriglyceridemia,
hypertension.
Furthermore,
90%
obese
patients
diabetes
have
Data
suggest
that
in
middle-aged
individuals
(especially
those
aged
45-54),
independent
risk
factor
for
plays
crucial
role
mediating
pathological
effects
observed.
Understanding
multifaceted
impact
heart,
muscle,
early
detection
stratification.
knowledge
timely
implementing
management
strategies
addressing
multi-organ
involvement
pathogenesis.
